These results indicate that even without affinity enhancement, 19305DP-TCR provides tumor-recognizing ability to both donor CD8+ and CD4+ T cells and has sufficient affinity which is comparable to affinity-enhanced or murine TCRs, and superior specificity, both of which are critical attributes for an ideal TCR to be utilized for clinical trials. Here, CD8A is linked to neoplasm.